Pub Date : 2022-10-01Epub Date: 2022-09-08DOI: 10.1080/17476348.2022.2114899
Sepideh Tahsini Tekantapeh, Morteza Ghojazadeh, Ali Akbar Ghamari, Aida Mohammadi, Hassan Soleimanpour
Background: Due to the high incidence and mortality of the worldwide COVID-19 pandemic, beneficial effects of effective antiviral and anti-inflammatory drugs used in other diseases, especially rheumatic diseases, were observed in the treatment of COVID-19.
Methods: Clinical and laboratory parameters of eight included cohort studies and five Randomized Control Trials between the baricitinib group and the control group were analyzed on the first day of admission and days 7, 14, and 28 during hospitalization.
Results: According to the meta-analysis result of eight included cohort studies with 2088 patients, the Pooled Risk Ratios were 0.46 (P < 0.001) for mortality, 6.14 (P < 0.001) for hospital discharge, and the mean differences of 76.78 (P < 0.001) for PaO2/FiO2 ratio was -47.32 (P = 0.02) for CRP, in the baricitinib group vs. control group on the seventh or fourteenth day of the treatment compared to the first day. Based on the meta-analysis of five RCT studies with 11,825 patients, the pooled RR was 0.84 (P = 0.001) for mortality and 1.07 (P = 0.014) for patients' recovery. The mean differences were -0.80 (P < 0.001) for hospitalization days, -0.51(P = 0.33) for time to recovery in the baricitinib group vs. control group.
Conclusions: Baricitinib prescription is strongly recommended in moderate to severe COVID-19.
{"title":"Therapeutic and anti-inflammatory effects of baricitinib on mortality, ICU transfer, clinical improvement, and CRS-related laboratory parameters of hospitalized patients with moderate to severe COVID-19 pneumonia: a systematic review and meta-analysis.","authors":"Sepideh Tahsini Tekantapeh, Morteza Ghojazadeh, Ali Akbar Ghamari, Aida Mohammadi, Hassan Soleimanpour","doi":"10.1080/17476348.2022.2114899","DOIUrl":"https://doi.org/10.1080/17476348.2022.2114899","url":null,"abstract":"<p><strong>Background: </strong>Due to the high incidence and mortality of the worldwide COVID-19 pandemic, beneficial effects of effective antiviral and anti-inflammatory drugs used in other diseases, especially rheumatic diseases, were observed in the treatment of COVID-19.</p><p><strong>Methods: </strong>Clinical and laboratory parameters of eight included cohort studies and five Randomized Control Trials between the baricitinib group and the control group were analyzed on the first day of admission and days 7, 14, and 28 during hospitalization.</p><p><strong>Results: </strong>According to the meta-analysis result of eight included cohort studies with 2088 patients, the Pooled Risk Ratios were 0.46 (P < 0.001) for mortality, 6.14 (P < 0.001) for hospital discharge, and the mean differences of 76.78 (P < 0.001) for PaO<sub>2</sub>/FiO<sub>2</sub> ratio was -47.32 (P = 0.02) for CRP, in the baricitinib group vs. control group on the seventh or fourteenth day of the treatment compared to the first day. Based on the meta-analysis of five RCT studies with 11,825 patients, the pooled RR was 0.84 (P = 0.001) for mortality and 1.07 (P = 0.014) for patients' recovery. The mean differences were -0.80 (P < 0.001) for hospitalization days, -0.51(P = 0.33) for time to recovery in the baricitinib group vs. control group.</p><p><strong>Conclusions: </strong>Baricitinib prescription is strongly recommended in moderate to severe COVID-19.</p>","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":" ","pages":"1109-1132"},"PeriodicalIF":3.9,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40637131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-01Epub Date: 2022-11-17DOI: 10.1080/17476348.2022.2145950
Eleni Xourgia, Dimitrios E Katsaros, Nikoleta A Xixi, Vasiliki Tsolaki, Christina Routsi, Spyros G Zakynthinos, Anastasia Kotanidou, Ilias I Siempos
Background: We attempted to investigate the change in mortality of intubated patients with coronavirus disease (COVID-19) from first to subsequent waves across several countries.
Methods: We pre-registered our meta-analysis with PROSPERO [Anonymized]. We searched PubMed, Scopus, and gray literature for observational studies reporting data on all-cause mortality of intubated patients with COVID-19 recruited both during first and subsequent waves of the pandemic. We considered studies published after 31 August 2020 up to 12 July 2021. The primary outcome of the meta-analysis was all-cause mortality. We used a random effects model to calculate pooled risk ratio (RR) and 95% confidence intervals (CI).
Results: By incorporating data of 363,660 patients from 43 countries included in 28 studies, we found that all-cause mortality of intubated patients with COVID-19 increased from first to subsequent waves (from 62.2% to 72.6%; RR 0.90, 95% CI 0.85-0.94, p < 0.00001). This finding was independent of the geo-economic variation of the included studies and persisted in several pre-specified subgroup and sensitivity analyses.
Conclusions: The robust finding of this meta-analysis suggests that mortality of intubated patients with COVID-19 did not improve over time. Future research should target this group of patients to further optimize their management.
背景:我们试图调查几个国家的冠状病毒病(COVID-19)插管患者从第一波到随后的死亡率变化。方法:我们在PROSPERO[匿名]预先注册了meta分析。我们检索了PubMed、Scopus和灰色文献,寻找报告在大流行的第一波和随后的浪潮中招募的COVID-19插管患者全因死亡率数据的观察性研究。我们考虑了2020年8月31日至2021年7月12日期间发表的研究。荟萃分析的主要结果是全因死亡率。我们使用随机效应模型计算合并风险比(RR)和95%置信区间(CI)。结果:通过纳入28项研究中来自43个国家的363,660例患者的数据,我们发现COVID-19插管患者的全因死亡率从第一波增加到随后的波(从62.2%增加到72.6%;RR 0.90, 95% CI 0.85-0.94, p < 0.00001)。这一发现独立于纳入研究的地理经济差异,并在几个预先指定的亚组和敏感性分析中持续存在。结论:这项荟萃分析的有力发现表明,COVID-19插管患者的死亡率并没有随着时间的推移而改善。未来的研究应针对这组患者进一步优化其管理。
{"title":"Mortality of intubated patients with COVID-19 during first and subsequent waves: a meta-analysis involving 363,660 patients from 43 countries.","authors":"Eleni Xourgia, Dimitrios E Katsaros, Nikoleta A Xixi, Vasiliki Tsolaki, Christina Routsi, Spyros G Zakynthinos, Anastasia Kotanidou, Ilias I Siempos","doi":"10.1080/17476348.2022.2145950","DOIUrl":"https://doi.org/10.1080/17476348.2022.2145950","url":null,"abstract":"<p><strong>Background: </strong>We attempted to investigate the change in mortality of intubated patients with coronavirus disease (COVID-19) from first to subsequent waves across several countries.</p><p><strong>Methods: </strong>We pre-registered our meta-analysis with PROSPERO [Anonymized]. We searched PubMed, Scopus, and gray literature for observational studies reporting data on all-cause mortality of intubated patients with COVID-19 recruited both during first and subsequent waves of the pandemic. We considered studies published after 31 August 2020 up to 12 July 2021. The primary outcome of the meta-analysis was all-cause mortality. We used a random effects model to calculate pooled risk ratio (RR) and 95% confidence intervals (CI).</p><p><strong>Results: </strong>By incorporating data of 363,660 patients from 43 countries included in 28 studies, we found that all-cause mortality of intubated patients with COVID-19 increased from first to subsequent waves (from 62.2% to 72.6%; RR 0.90, 95% CI 0.85-0.94, p < 0.00001). This finding was independent of the geo-economic variation of the included studies and persisted in several pre-specified subgroup and sensitivity analyses.</p><p><strong>Conclusions: </strong>The robust finding of this meta-analysis suggests that mortality of intubated patients with COVID-19 did not improve over time. Future research should target this group of patients to further optimize their management.</p>","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":" ","pages":"1101-1108"},"PeriodicalIF":3.9,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40675899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-01Epub Date: 2022-11-18DOI: 10.1080/17476348.2022.2145947
Matthew M Smith, Lauren S Buck
Introduction: Laryngotracheal stenosis comprises a broad spectrum of congenital and acquired conditions that commonly cause pediatric airway obstruction. With the introduction and popularization of operative procedures such as laryngotracheoplasty, cricotracheal resection, and slide tracheoplasty more patients are presenting with airway issues at multiple anatomic levels. A combination of endoscopic and open techniques continues to be utilized for these complex issues. Additionally, there are specific long-term considerations for the post reconstruction patient.
Areas covered: This review highlights important aspects of the diagnosis, work up, and surgical treatment of pediatric laryngotracheal stenosis with updates for revision airway surgery and the post reconstruction patient. Important research articles and techniques within pediatric airway reconstruction are summarized and included in the review, in addition to recent articles from the last five years on pediatric laryngotracheal stenosis which were identified through a search of the PubMed database.
Expert opinion: The multidisciplinary concept of evaluation and treatment of laryngotracheal stenosis continues to be essential. Revision airway surgery presents unique challenges to improve the quality of life of patients as they age after reconstruction. Tracheal transplantation remains an important research area in the treatment of laryngotracheal stenosis.
{"title":"Update on the diagnosis and management of pediatric laryngotracheal stenosis.","authors":"Matthew M Smith, Lauren S Buck","doi":"10.1080/17476348.2022.2145947","DOIUrl":"https://doi.org/10.1080/17476348.2022.2145947","url":null,"abstract":"<p><strong>Introduction: </strong>Laryngotracheal stenosis comprises a broad spectrum of congenital and acquired conditions that commonly cause pediatric airway obstruction. With the introduction and popularization of operative procedures such as laryngotracheoplasty, cricotracheal resection, and slide tracheoplasty more patients are presenting with airway issues at multiple anatomic levels. A combination of endoscopic and open techniques continues to be utilized for these complex issues. Additionally, there are specific long-term considerations for the post reconstruction patient.</p><p><strong>Areas covered: </strong>This review highlights important aspects of the diagnosis, work up, and surgical treatment of pediatric laryngotracheal stenosis with updates for revision airway surgery and the post reconstruction patient. Important research articles and techniques within pediatric airway reconstruction are summarized and included in the review, in addition to recent articles from the last five years on pediatric laryngotracheal stenosis which were identified through a search of the PubMed database.</p><p><strong>Expert opinion: </strong>The multidisciplinary concept of evaluation and treatment of laryngotracheal stenosis continues to be essential. Revision airway surgery presents unique challenges to improve the quality of life of patients as they age after reconstruction. Tracheal transplantation remains an important research area in the treatment of laryngotracheal stenosis.</p>","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":" ","pages":"1035-1041"},"PeriodicalIF":3.9,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40687652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-01Epub Date: 2022-10-05DOI: 10.1080/17476348.2022.2131543
Hela Attia, Helmi Ben Saad, Karim Masmoudi, Imen Bannour, Mouna Ouaz, Kais Gardabbou, Ali Majdoub
Objective: To determine the predictive factors of nebulized morphine (nMOR) failure in patients with chest trauma.
Research design and methods: This was an interventional clinical study. Patients admitted with isolated chest trauma with a pain visual analog score > 4 were included. Each patient received 10 mg nMOR. If pain was still > 4 after 10 minutes of nebulization, the latter was repeated every 10 minutes until pain was relieved (i.e. ≤ 4). If pain was > 4 at 30 minutes, nMOR was considered a failure. Patients were divided into two groups: MOR (+) and MOR (-) (good response to and nMOR failure, respectively).
Results: Seventy-five patients were included. Analysis of the risk factors revealed that road traffic accidents (relative risk (RR): 0.117 [0.031-0.443]; p = 0.002), number of fractured ribs > 4 (RR: 0.317 [0.092-0.543]; p = 0.006), bilateral injury (RR: 0.114 [0.037-0.349]; p < 0.001), flail chest (RR: 0.120 [0.037-0.386]; p < 0.001), hemothorax (RR: 0.203 [0.062-0.660]; p = 0.008), pulmonary contusion (RR: 0.202 [0.069-0.589]; p = 0.003), and pain at admission > 7 (RR: 0.363 [0.147-0.579]; p = 0.004) were predictors of nMOR failure.
Conclusion: Our results can help optimize the analgesic management of chest trauma patients by identifying the most eligible patients to benefit from nMOR.
Clinical trial registration: www.clinicaltrials.gov identifier is NCT03580187.
{"title":"Predictive factors of nebulized morphine failure in North-African patients with chest trauma: a prospective pilot study.","authors":"Hela Attia, Helmi Ben Saad, Karim Masmoudi, Imen Bannour, Mouna Ouaz, Kais Gardabbou, Ali Majdoub","doi":"10.1080/17476348.2022.2131543","DOIUrl":"https://doi.org/10.1080/17476348.2022.2131543","url":null,"abstract":"<p><strong>Objective: </strong>To determine the predictive factors of nebulized morphine (nMOR) failure in patients with chest trauma.</p><p><strong>Research design and methods: </strong>This was an interventional clinical study. Patients admitted with isolated chest trauma with a pain visual analog score > 4 were included. Each patient received 10 mg nMOR. If pain was still > 4 after 10 minutes of nebulization, the latter was repeated every 10 minutes until pain was relieved (i.e. ≤ 4). If pain was > 4 at 30 minutes, nMOR was considered a failure. Patients were divided into two groups: MOR (+) and MOR (-) (good response to and nMOR failure, respectively).</p><p><strong>Results: </strong>Seventy-five patients were included. Analysis of the risk factors revealed that road traffic accidents (relative risk (RR): 0.117 [0.031-0.443]; p = 0.002), number of fractured ribs > 4 (RR: 0.317 [0.092-0.543]; p = 0.006), bilateral injury (RR: 0.114 [0.037-0.349]; p < 0.001), flail chest (RR: 0.120 [0.037-0.386]; p < 0.001), hemothorax (RR: 0.203 [0.062-0.660]; p = 0.008), pulmonary contusion (RR: 0.202 [0.069-0.589]; p = 0.003), and pain at admission > 7 (RR: 0.363 [0.147-0.579]; p = 0.004) were predictors of nMOR failure.</p><p><strong>Conclusion: </strong>Our results can help optimize the analgesic management of chest trauma patients by identifying the most eligible patients to benefit from nMOR.</p><p><strong>Clinical trial registration: </strong>www.clinicaltrials.gov identifier is NCT03580187.</p>","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":"16 10","pages":"1085-1092"},"PeriodicalIF":3.9,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33488406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-01DOI: 10.1080/17476348.2022.2115361
Zexi Liao, Minhan Yi, Jiaxin Li, Yuan Zhang
Background: The results of associations between single nucleotide polymorphisms (SNPs) of genes in DNA repairing pathway and lung cancer (LC) risk are inconsistent.
Methods: We applied allele, dominant and recessive models to explore the risk of researched variants to LC in total LC and subgroups by ethnicity or LC subtypes with a cutoff point of p < 0.05.
Results: A total of 76,935 cases and 88,649 controls from 192 articles were included. Among the analyzed 40 variants from 20 genes, we found 9 statistically significant variants in overall populations by allele model, including five SNPs (rs1760944, rs9344, rs13181, rs1001581, and rs915927) increasing LC risk (odd ratios [ORs] = 1.10-1.71) and four SNPs (rs1042522, rs3213245, rs11615, and rs238406) decreasing the risk (ORs = 0.75-0.94). We identified rs1042522 and rs13181 as significant variants for LC in three models. Additionally, we identified differential significant SNPs in ethnic and subtype's analysis with comparison to total population.
Conclusions: There are five SNPs in DNA repairing pathway associated with increased LC risk and four others decreased LC risk. Besides, the risky SNPs in different ethnicities and various LC subtypes were partly different, and the contribution of different genotypes to risk alleles were various as well.
{"title":"DNA repair in lung cancer: a large-scale quantitative analysis for polymorphisms in DNA repairing pathway genes and lung cancer susceptibility.","authors":"Zexi Liao, Minhan Yi, Jiaxin Li, Yuan Zhang","doi":"10.1080/17476348.2022.2115361","DOIUrl":"https://doi.org/10.1080/17476348.2022.2115361","url":null,"abstract":"<p><strong>Background: </strong>The results of associations between single nucleotide polymorphisms (SNPs) of genes in DNA repairing pathway and lung cancer (LC) risk are inconsistent.</p><p><strong>Methods: </strong>We applied allele, dominant and recessive models to explore the risk of researched variants to LC in total LC and subgroups by ethnicity or LC subtypes with a cutoff point of <i>p</i> < 0.05.</p><p><strong>Results: </strong>A total of 76,935 cases and 88,649 controls from 192 articles were included. Among the analyzed 40 variants from 20 genes, we found 9 statistically significant variants in overall populations by allele model, including five SNPs (rs1760944, rs9344, rs13181, rs1001581, and rs915927) increasing LC risk (odd ratios [ORs] = 1.10-1.71) and four SNPs (rs1042522, rs3213245, rs11615, and rs238406) decreasing the risk (ORs = 0.75-0.94). We identified rs1042522 and rs13181 as significant variants for LC in three models. Additionally, we identified differential significant SNPs in ethnic and subtype's analysis with comparison to total population.</p><p><strong>Conclusions: </strong>There are five SNPs in DNA repairing pathway associated with increased LC risk and four others decreased LC risk. Besides, the risky SNPs in different ethnicities and various LC subtypes were partly different, and the contribution of different genotypes to risk alleles were various as well.</p>","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":"16 9","pages":"997-1010"},"PeriodicalIF":3.9,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10447228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-01Epub Date: 2022-09-22DOI: 10.1080/17476348.2022.2126355
Pooja Devani, David K H Lo, Erol A Gaillard
Introduction: Asthma is a chronic airways disease characterized by episodes of wheeze, chest tightness, and evidence of reversible airflow obstruction. Symptoms are frequently triggered by exercise, exposure to aeroallergens, and respiratory viruses. It is the commonest non-communicable respiratory condition in children, affecting over 5.5 million children in the European Union alone. Both over- and under- diagnosis of asthma are common for several reasons.
Areas covered: The diagnosis is frequently based on parental or patient reported non-specific symptoms alone. All major asthma guidelines now recommend the use of objective tests, including spirometry, bronchodilator reversibility testing, fraction of exhaled nitric oxide measurements and challenge testing to confirm the diagnosis. Recently, the European Respiratory Society published the first evidence-based international guidelines for diagnosing asthma in school-age children using objective measures. Major barriers to implementation in primary care and less well-resourced healthcare settings are access to relevant objective tests for children and quality assurance to obtain reliable results.
Expert opinion: We highlight the importance of diagnosing asthma in school-age children using objective tests and outline a practical approach for the use of widely available tests. We also review challenges and barriers to implementation of objective testing in children managed outside specialist settings.
{"title":"Practical approaches to the diagnosis of asthma in school-age children.","authors":"Pooja Devani, David K H Lo, Erol A Gaillard","doi":"10.1080/17476348.2022.2126355","DOIUrl":"https://doi.org/10.1080/17476348.2022.2126355","url":null,"abstract":"<p><strong>Introduction: </strong>Asthma is a chronic airways disease characterized by episodes of wheeze, chest tightness, and evidence of reversible airflow obstruction. Symptoms are frequently triggered by exercise, exposure to aeroallergens, and respiratory viruses. It is the commonest non-communicable respiratory condition in children, affecting over 5.5 million children in the European Union alone. Both over- and under- diagnosis of asthma are common for several reasons.</p><p><strong>Areas covered: </strong>The diagnosis is frequently based on parental or patient reported non-specific symptoms alone. All major asthma guidelines now recommend the use of objective tests, including spirometry, bronchodilator reversibility testing, fraction of exhaled nitric oxide measurements and challenge testing to confirm the diagnosis. Recently, the European Respiratory Society published the first evidence-based international guidelines for diagnosing asthma in school-age children using objective measures. Major barriers to implementation in primary care and less well-resourced healthcare settings are access to relevant objective tests for children and quality assurance to obtain reliable results.</p><p><strong>Expert opinion: </strong>We highlight the importance of diagnosing asthma in school-age children using objective tests and outline a practical approach for the use of widely available tests. We also review challenges and barriers to implementation of objective testing in children managed outside specialist settings.</p>","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":" ","pages":"973-981"},"PeriodicalIF":3.9,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40372017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-01Epub Date: 2022-10-13DOI: 10.1080/17476348.2022.2130767
Ahmad Abu Qubo, Anjali Saqi, Mary M Salvatore
The temporal heterogeneity that is a part of the pathologic UIP diagnosis can also be observed on chest CT. Earliest CT features of UIP include sub-pleural, basilar predominant opacities, and traction bronchiectasis. Late UIP presents radiographically with honeycombing that tends to increase in its peripheral extent and thickness over time. Temporal heterogeneity is manifest on CT with isolated areas of traction bronchiectasis representing early disease and separate areas of honeycombing representing more advanced disease in the same patient. Furthermore, some patients evolve from a probable UIP pattern to a UIP pattern. Therefore, a probable UIP pattern with its traction bronchiectasis and absence of honeycombing is an early UIP pattern. The most important questions become "Will it progress" and "Why should it not progress"?
{"title":"The temporal heterogeneity of usual interstitial pneumonia on chest CT.","authors":"Ahmad Abu Qubo, Anjali Saqi, Mary M Salvatore","doi":"10.1080/17476348.2022.2130767","DOIUrl":"https://doi.org/10.1080/17476348.2022.2130767","url":null,"abstract":"The temporal heterogeneity that is a part of the pathologic UIP diagnosis can also be observed on chest CT. Earliest CT features of UIP include sub-pleural, basilar predominant opacities, and traction bronchiectasis. Late UIP presents radiographically with honeycombing that tends to increase in its peripheral extent and thickness over time. Temporal heterogeneity is manifest on CT with isolated areas of traction bronchiectasis representing early disease and separate areas of honeycombing representing more advanced disease in the same patient. Furthermore, some patients evolve from a probable UIP pattern to a UIP pattern. Therefore, a probable UIP pattern with its traction bronchiectasis and absence of honeycombing is an early UIP pattern. The most important questions become \"Will it progress\" and \"Why should it not progress\"?","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":" ","pages":"959-961"},"PeriodicalIF":3.9,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40380969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-01Epub Date: 2022-09-28DOI: 10.1080/17476348.2022.2128335
Tommaso Pettenuzzo, Nicolò Sella, Francesco Zarantonello, Alessandro De Cassai, Federico Geraldini, Paolo Persona, Elisa Pistollato, Annalisa Boscolo, Paolo Navalesi
Introduction: Patient self-inflicted lung injury (P-SILI) has been proposed as a form of lung injury caused by strong inspiratory efforts consequent to a high respiratory drive in patients with hypoxemic acute respiratory failure (hARF). Increased respiratory drive and effort may lead to variable combinations of deleterious phenomena, such as excessive transpulmonary pressure, pendelluft, intra-tidal recruitment, local lung volutrauma, and pulmonary edema. Gas exchange and respiratory mechanics derangements further increase respiratory drive and effort, thus inducing a vicious circle. Forms of partial ventilatory support may further add to the detrimental effects of P-SILI. Since P-SILI may worsen patient outcome, strategies aimed at identifying and preventing P-SILI would be of great importance.
Areas covered: We systematically searched Pubmed since inception until 15 April 2022 to review the patho-physiological mechanisms of P-SILI and the strategies to identify those patients at risk of P-SILI.
Expert opinion: Although the concept of P-SILI has been increasingly supported by experimental and clinical data, no study has insofar demonstrated the efficacy of any strategy to identify it in the clinical setting. Further research is thus needed to ascertain the detrimental effects of spontaneous breathing and identify patients with hARF at high risk of developing P-SILI.
{"title":"How to recognize patients at risk of self-inflicted lung injury.","authors":"Tommaso Pettenuzzo, Nicolò Sella, Francesco Zarantonello, Alessandro De Cassai, Federico Geraldini, Paolo Persona, Elisa Pistollato, Annalisa Boscolo, Paolo Navalesi","doi":"10.1080/17476348.2022.2128335","DOIUrl":"https://doi.org/10.1080/17476348.2022.2128335","url":null,"abstract":"<p><strong>Introduction: </strong>Patient self-inflicted lung injury (P-SILI) has been proposed as a form of lung injury caused by strong inspiratory efforts consequent to a high respiratory drive in patients with hypoxemic acute respiratory failure (hARF). Increased respiratory drive and effort may lead to variable combinations of deleterious phenomena, such as excessive transpulmonary pressure, <i>pendelluft</i>, intra-tidal recruitment, local lung volutrauma, and pulmonary edema. Gas exchange and respiratory mechanics derangements further increase respiratory drive and effort, thus inducing a vicious circle. Forms of partial ventilatory support may further add to the detrimental effects of P-SILI. Since P-SILI may worsen patient outcome, strategies aimed at identifying and preventing P-SILI would be of great importance.</p><p><strong>Areas covered: </strong>We systematically searched Pubmed since inception until 15 April 2022 to review the patho-physiological mechanisms of P-SILI and the strategies to identify those patients at risk of P-SILI.</p><p><strong>Expert opinion: </strong>Although the concept of P-SILI has been increasingly supported by experimental and clinical data, no study has insofar demonstrated the efficacy of any strategy to identify it in the clinical setting. Further research is thus needed to ascertain the detrimental effects of spontaneous breathing and identify patients with hARF at high risk of developing P-SILI.</p>","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":" ","pages":"963-971"},"PeriodicalIF":3.9,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33481617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-01Epub Date: 2022-09-26DOI: 10.1080/17476348.2022.2126354
Samir Shah, Dahnish Valiani, Omotola Balogun, Martin Angelo Zanoria, Simone Jarrett, Raul Hiedra, Gabriel Patarroyo-Aponte, Zurab Azmaiparashvili, Kevin Bryan Lo, Glenn Eiger
Background: Coronavirus disease 2019 (COVID-19) may result in rapid onset of hypoxemic respiratory failure. This study aimed to characterize the factors and outcomes associated with prolonged hypoxia in patients with COVID-19. Prolonged severe hypoxia (PSH) was defined as hypoxia requiring ≥6 L/min of oxygen by nasal cannula or equivalent for more than 10 days.
Research design and methods: This study was designed as a single-center retrospective analysis. Multivariable logistic regression was utilized to assess factors associated with PSH.
Results: The sample included 554 patients with 117 (21%) having PSH. Median length of stay of patients with PSH was significantly longer (median IQR: 18 days vs 6 days, p < 0.0001). Patients with PSH had significantly higher rates of venous thromboembolism (p < 0.0001) and major bleeding (p < 0.004). The presence of cirrhosis (OR 3.32, 95% CI [1.02 to 10.83]) and hypertension (OR 1.99, 95% CI [1.12 to 3.53]) were independently associated with PSH, while outpatient use of anti-platelet agents had an inverse association (OR 0.57, 95% CI [0.36 to 0.91]).
Conclusion: PSH is associated with increased length of stay, morbidity, and mortality. Hypertension and liver cirrhosis were significantly associated with higher odds of PSH, while use of anti-platelet therapy had a protective effect.
{"title":"Demographic and clinical profile of patients suffering prolonged severe hypoxia in COVID-19.","authors":"Samir Shah, Dahnish Valiani, Omotola Balogun, Martin Angelo Zanoria, Simone Jarrett, Raul Hiedra, Gabriel Patarroyo-Aponte, Zurab Azmaiparashvili, Kevin Bryan Lo, Glenn Eiger","doi":"10.1080/17476348.2022.2126354","DOIUrl":"https://doi.org/10.1080/17476348.2022.2126354","url":null,"abstract":"<p><strong>Background: </strong>Coronavirus disease 2019 (COVID-19) may result in rapid onset of hypoxemic respiratory failure. This study aimed to characterize the factors and outcomes associated with prolonged hypoxia in patients with COVID-19. Prolonged severe hypoxia (PSH) was defined as hypoxia requiring ≥6 L/min of oxygen by nasal cannula or equivalent for more than 10 days.</p><p><strong>Research design and methods: </strong>This study was designed as a single-center retrospective analysis. Multivariable logistic regression was utilized to assess factors associated with PSH.</p><p><strong>Results: </strong>The sample included 554 patients with 117 (21%) having PSH. Median length of stay of patients with PSH was significantly longer (median IQR: 18 days vs 6 days, p < 0.0001). Patients with PSH had significantly higher rates of venous thromboembolism (p < 0.0001) and major bleeding (p < 0.004). The presence of cirrhosis (OR 3.32, 95% CI [1.02 to 10.83]) and hypertension (OR 1.99, 95% CI [1.12 to 3.53]) were independently associated with PSH, while outpatient use of anti-platelet agents had an inverse association (OR 0.57, 95% CI [0.36 to 0.91]).</p><p><strong>Conclusion: </strong>PSH is associated with increased length of stay, morbidity, and mortality. Hypertension and liver cirrhosis were significantly associated with higher odds of PSH, while use of anti-platelet therapy had a protective effect.</p>","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":" ","pages":"1017-1021"},"PeriodicalIF":3.9,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40369177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Whether sonographic features of mediastinal lymph nodes can differentiate malignancy from tuberculosis remains unclear.
Research design and methods: We retrospectively identified subjects with a confirmed diagnosis of tuberculosis or malignancy on endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA). Our primary objective was to compare the endosonographic characteristics of lymph nodes on EBUS between tuberculosis and malignancy. Our secondary objective was to assess the diagnostic performance of endosonographic characteristics in predicting malignancy.
Results: We included 774 subjects (1,498 lymph nodes) with a confirmed diagnosis of tuberculosis (n = 497) or malignancy (n = 277). Distinct lymph node margins (84.1% vs. 93.8%, P < 0.001) and coagulation necrosis sign (11.2% vs. 29.8%, P < 0.001) were less common in malignancy than tuberculosis. The absence of central hilar structure had the highest sensitivity (92.1%) for malignancy. Endosonographic characteristics had poor specificity for malignancy(round shape and coagulation necrosis sign, 77.3% and 70.2%. In multivariate analysis, coagulation necrosis sign was associated with a lower odds of malignancy (odds ratio 0.45 [95% confidence intervals, 0.21-0.95]).
Conclusions: Endosonographic characteristics, such as round shape and the coagulation necrosis sign, are not specific for malignancy in high tuberculosis prevalence areas.
背景:纵隔淋巴结的声像图特征是否能鉴别恶性与结核尚不清楚。研究设计和方法:我们回顾性地选取经支气管超声引导下经支气管针吸(EBUS-TBNA)确诊为结核或恶性肿瘤的受试者。我们的主要目的是比较结核和恶性EBUS淋巴结的超声特征。我们的次要目的是评估超声特征在预测恶性肿瘤中的诊断性能。结果:我们纳入了确诊为肺结核(n = 497)或恶性肿瘤(n = 277)的774名受试者(1498个淋巴结)。结论:在结核病高发地区,淋巴结边缘明显(84.1% vs. 93.8%, P):超声特征,如圆形和凝血坏死征象并不是恶性肿瘤的特异性征象。
{"title":"Endosonographic characteristics of mediastinal lymph nodes for predicting malignancy in high tuberculosis burden settings: a study of 774 subjects.","authors":"Kuruswamy Thurai Prasad, Valliappan Muthu, Inderpaul Singh Sehgal, Sahajal Dhooria, Navneet Singh, Nalini Gupta, Ashutosh Nath Aggarwal, Ritesh Agarwal","doi":"10.1080/17476348.2022.2118717","DOIUrl":"https://doi.org/10.1080/17476348.2022.2118717","url":null,"abstract":"<p><strong>Background: </strong>Whether sonographic features of mediastinal lymph nodes can differentiate malignancy from tuberculosis remains unclear.</p><p><strong>Research design and methods: </strong>We retrospectively identified subjects with a confirmed diagnosis of tuberculosis or malignancy on endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA). Our primary objective was to compare the endosonographic characteristics of lymph nodes on EBUS between tuberculosis and malignancy. Our secondary objective was to assess the diagnostic performance of endosonographic characteristics in predicting malignancy.</p><p><strong>Results: </strong>We included 774 subjects (1,498 lymph nodes) with a confirmed diagnosis of tuberculosis (n = 497) or malignancy (n = 277). Distinct lymph node margins (84.1% vs. 93.8%, P < 0.001) and coagulation necrosis sign (11.2% vs. 29.8%, P < 0.001) were less common in malignancy than tuberculosis. The absence of central hilar structure had the highest sensitivity (92.1%) for malignancy. Endosonographic characteristics had poor specificity for malignancy(round shape and coagulation necrosis sign, 77.3% and 70.2%. In multivariate analysis, coagulation necrosis sign was associated with a lower odds of malignancy (odds ratio 0.45 [95% confidence intervals, 0.21-0.95]).</p><p><strong>Conclusions: </strong>Endosonographic characteristics, such as round shape and the coagulation necrosis sign, are not specific for malignancy in high tuberculosis prevalence areas.</p>","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":" ","pages":"1011-1015"},"PeriodicalIF":3.9,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33441685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}